Advanced Search
MyIDEAS: Login

Advances in Cancer Therapeutics and Patient Access to New Drugs


Author Info

  • George Dranitsaris

    (Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa)

  • Ilse Truter

    (Department of Pharmacy, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa)

  • Martie S. Lubbe

    (School of Pharmacy, North-West University, Potchefstroom, South Africa)

  • Eitan Amir

    (Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada)

  • William Evans

    (Department of Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada)

Registered author(s):


    Globally, there are approximately 7.4 million cancer deaths annually, approximately 13% of deaths from all causes. Cancer is a disease of older people and, as the population ages over the next 10-20 years, we can expect an increase in the cancer incidence. Encouragingly, cancer mortality has stabilized in many countries. Part of this success may be attributed to the development of new cancer agents, collectively called 'targeted therapies', that are more specific to key components of tumour growth. Worldwide, however, one of the main factors that limit patient access to these important new drugs is their cost, which is higher than traditional chemotherapy. In this review, the clinical and pharmacoeconomic data of selected targeted agents are discussed. In the second part of this article, the challenges faced by healthcare systems in making such drugs available to patients is reviewed. Current strategies used by many countries around the world to manage cancer drug budgets are presented, along with a proposed approach using pharmacoeconomic methodology that may increase patient access.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL:
    Download Restriction: Pay per view

    File URL:
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

    Volume (Year): 29 (2011)
    Issue (Month): 3 ()
    Pages: 213-224

    as in new window
    Handle: RePEc:wkh:phecon:v:29:y:2011:i:3:p:213-224

    Contact details of provider:
    Web page:

    Related research

    Keywords: Bevacizumab; therapeutic use; Cancer; treatment; Cetuximab; therapeutic use; Drug-cost; Formularies; Imatinib; therapeutic use; Monoclonal-antibodies; therapeutic use; Rituximab; therapeutic use; Trastuzumab; therapeutic use.;

    Find related papers by JEL classification:


    No references listed on IDEAS
    You can help add them by filling out this form.


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as in new window

    Cited by:
    1. Bonastre, Julia & Chevalier, Julie & Van der Laan, Chantal & Delibes, Michel & De Pouvourville, Gerard, 2014. "Access to innovation: Is there a difference in the use of expensive anticancer drugs between French hospitals?," Health Policy, Elsevier, vol. 116(2), pages 162-169.


    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.


    Access and download statistics


    When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:29:y:2011:i:3:p:213-224. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.